Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820029 | 0.90 | MAPT (0.65) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL944105 | 0.89 | MAPT (0.68) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| Ethylene SCHEMBL2709825 | 0.86 | MAPT (0.64) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL14637706 | 0.83 | MAPT (0.70) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL15271381 | 0.79 | SIRT6 (0.81) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL6151230 | 0.79 | SIRT6 (0.81) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL6609282 | 0.79 | MEN1 (1.00) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL1646891 | 0.77 | MAPT (0.66) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL1851861 | 0.76 | MAPT (0.89) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL378458 | 0.76 | MAPT (0.96) | KMT2AMEN1MAPTALDH1A1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218348-A1 | METHOD FOR SYNTHESIZING LACTAM COMPOUNDS | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2022-10-20 | — | — | WO | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| WO-2008062182-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | KMT2A 3693/4885MEN1 221/4885MAPT 1771/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | KMT2A 1472/4885MEN1 281/4885MAPT 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.